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Abstract 
Background and purpose: Real time adaptive radiotherapy that enables smaller 
irradiated volumes may reduce pulmonary toxicity. We report on the first patient 
treatment of electromagnetic-guided real time adaptive radiotherapy delivered with 
MLC tracking for lung stereotactic ablative body radiotherapy. 
Materials and methods: A clinical trial was developed to investigate the safety and 
feasibility of MLC tracking in lung. The first patient was an 80-year old man with a 
single left lower lobe lung metastasis to be treated with SABR to 48 Gy in 4 fractions. 
In–house software was integrated with a standard linear accelerator to adapt the 
treatment beam shape and position based on electromagnetic transponders implanted in 
the lung. MLC tracking plans were compared against standard ITV-based treatment 
planning. MLC tracking plan delivery was reconstructed in the patient to confirm safe 
delivery. 
Results: Real time adaptive radiotherapy delivered with MLC tracking compared to 
standard ITV-based planning reduced the PTV by 41% (18.7–11 cm3) and the mean 
lung dose by 30% (202–140 cGy), V20 by 35% (2.6–1.5%) and V5 by 9% (8.9–8%). 
Conclusion: An emerging technology, MLC tracking, has been translated into the clinic 
and used to treat lung SABR patients for the first time. This milestone represents an 
important first step for clinical real-time adaptive radiotherapy that could reduce 
pulmonary toxicity in lung radiotherapy. 
 
  
 
 
 
 
Introduction 
Stereotactic Ablative Body Radiotherapy (SABR) for lesions in the lung has shown 
substantially improved 5 year survival compared to conventionally fractionated treatments 
[1–3]. Comparison with surgery outcomes is favourable in weighted cohorts [4]. However, 
further application of lung SABR based on lesion size, proximity to central structures and 
dose level/fractionation has been limited by toxicity [5,6]. Legitimate reduction of margins 
with utilisation of more accurate, real-time motion adaptive, treatment delivery will 
directly reduce the irradiated volume and potentially toxicity. 
For lung lesions, treatment delivery ideally needs to localise and adapt in real-time to account 
for variable inter- and intra-fraction tumour motion, to remove interplay for dynamic 
treatment, and to permit high efficiency. Critically, lung SABR planning is typically 
generated from 4DCT; growing evidence suggests motion at this single time point may not 
be representative of motion experienced during the short course treatment [7,8]. 
Real time guidance and adaptation has been clinically applied on specialised robotic and 
gimballed linear accelerators for lung SABR and both techniques have demonstrated 
significant reductions in treated volumes [9,10]. Another real-time image guidance and 
adaption technique, electromagnetic (EM) guided MLC tracking, is expected to match 
reductions in treated volumes to robotic and gimbal modalities [11,12]. MLC tracking 
began treating prostate cancer patients in 2013 [13] and demonstrated high fidelity of 
delivered dose, including dose painting, to moving targets [14]. However, to date MLC 
tracking has only been used clinically to treat prostate cancer, which exhibits occasional 
slow motion. In this work we apply MLC tracking to lung cancer, which exhibits constant 
and complex motion. We present the first-in-human study to clinically realise the benefits 
of real time adaptation on a standard linac for lung SABR. We describe our experience with 
the first patient. 
 
  
Materials and methods 
 
Clinical trial protocol and patients 
The Lung Intensity Guided Hypofractionated Tumour tracking SABR (LIGHT SABR) study 
is a single institution investigator-led Phase I/II clinical trial with full local ethics approval 
and registration (NCT02514512). The primary endpoint is that 90% of treatments are 
delivered without MLC tracking related software failures, isolated as failure to deliver 
treatment with MLC tracking treatment caused directly by malfunction of the MLC tracking 
software. The trial will recruit 20 patients with stage I NSCLC or 1–3 oligometastases. 
Patients will be treated with electromagnetic-guided real-time adaptation with MLC tracking 
utilising Calypso lung transponders (Varian Medical Systems, Palo Alto) to provide the real-
time motion signal. The workflow is shown in Fig. 1. The use of in-house MLC tracking 
software was registered with the Therapeutic Goods Administration in Australia utilising the 
Clinical Trial Notification system. 
 
MLC tracking with electromagnetic-guidance 
Three Calypso lung transponders were implanted one week prior to simulation using 
standard fiberoptic bronchoscopy with radial endobronchial ultrasound and X-ray image 
guidance. Transponders were placed as close as possible to the target lesion. Beacon 
migration and accuracy as a surrogate of lesion position were evaluated prior to treatment 
in 4DCT and during treatment with CBCT and fluoroscopic imaging. Beacon centroid to 
lesion centroid in each phase of the 4DCT was measured to describe the relative motion 
normalised to end of exhale. Surrogacy error was defined as the difference in beacon 
centroid and tumour centroid position in each phase. Prior to treatment, planning 
contours for PTV and transponders were overlayed on the CBCT to assess potential 
migration and alignment. Additionally, fluoroscopic imaging with a field encompassing 
lesion and transponders was acquired over three breathing cycles at two orthogonal angles 
prior to treatment for retrospective assessment of tumour/beacon motion with respiration; 
and fluoroscopic imaging was acquired during treatment for retrospective assessment of 
tumour motion during treatment. 
The planning 4DCT scan was performed using an external surrogate for respiratory motion, 
Philips bellows (Philips Medical Systems, Cleveland) for 4DCT, with the patient free-
breathing and positioned in a BodyFixTM device with arms above head. 
Treatment plans were created in the Eclipse planning system (v.11, Varian Medical 
Systems, Palo Alto) for a 6 MV dual RapidArc delivery utilising the AAA algorithm. 
The collimator was angled to align with the major motion axis of the lesion (superior–
inferior) and the arcs rotated between 90 and 270 degrees (Varian IEC). Plan complexity 
was recorded using the modulation complexity score (MCS) which has been shown to 
correlate with delivery accuracy and can affect tracking performance above a 0.8 
threshold [15,16]. Treatment planning was performed for MLC tracking, and for 
comparison (and back-up in case of MLC tracking failure) a ‘conventional’ ITV-based 
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plan was also created. MLC tracking plans utilised the end-of-exhale phase as a 
reference phase to define the GTVTracking, with the CTV defined as being equal to the 
GTV and a 5 mm CTV to PTV margin. The end-of-exhale phase assures a proper 
localisation and delineation of the tumour [17– 19] while the 5 mm margin has been 
described in the literature to be  sufficient to  account for tracking system latency up 
to  500 ms [20] and differences in tumour sizes and shape during respiration [21]. The 
exhale phase CT scan is likely to have the fewest imaging artefacts, and having the 
smallest lung volume, is likely to over-, rather than under-estimate the actual lung dose. 
The conventional plan was established for an ITV derived from the 4DCT which 
included the GTV in each breathing phase. The ITV was expanded by 5 mm to create 
the PTV. The conventional plan was calculated on a mean CT image from 4DCT. Both 
plans met the dose volume criteria of RTOG 0915 [22]. The fractionation scheme was 
48 Gy in four fractions delivered to greater than 95% of the PTV. At treatment sessions 
the patient was aligned to lasers in the, BodyFix device and Philips bellows were 
attached to record the breathing signal during treatment. For each fraction, CBCT was 
acquired and a best-fit alignment to the transponders was performed. The PTV 
structure was then overlaid to confirm tumour coverage based on beacon localisation. 
The patient was treated with Calypso-guided MLC tracking [23]. We utilise the kernel 
density estimation prediction algorithm [24] to account for the system’s 220 ms 
latency [13]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 1. Schematic of the MLC tracking control system used for the clinical trial. 
Electromagnetic transponders send real-time localisation to the MLC tracking 
system which updates the MLC pattern and sends these new leaf positions to the 
MLC controller for treatment at the linac. 
  
Quality assurance (QA) regime 
Quality assurance before, during and after treatment is essential, particularly with research 
software controlling the treatment unit. Standard quality assurance measures for SABR 
treatment were utilised including secondary monitor units check and fluence delivery [25]. 
Further quality measures, based on Failure Mode and Effects Analysis [26] and broad 
discussion with international thought leaders on MLC tracking safety, were implemented. 
These extra measures included: 
 
• MLC tracking patient-specific QA incorporating review of over- and under-dose 
areas of patient plan with patient-specific motion [27], 
• Checklist applied to additional MLC tracking-specific workflow steps, 
• Pre-treatment delivery to a Delta4 phantom (ScandiDos, Swe- den) with and 
without motion (patient-specific with HexaMotion (Scandidos, Sweden)), 
• Pre-treatment fluoroscopy to interrogate Calypso beacon motion migration and 
surrogacy to tumour, and post- treatment dose reconstruction [28,29]. 
 
MLC tracking errors were reported using the areas of under- and over-dose (Au and Ao 
respectively) between the plan and delivery, as developed by Poulsen[29]. The under- and 
over-dose areas have been shown to correlate with dose delivery errors and clearly artic- 
ulate the contribution of leaf adjustment error, leaf fitting, and target localisation to the 
MLC tracking performance. Treatment log files including MLC motion, Calypso 
trajectories, kV and MV images and Philips bellows motion were recorded. 
Dose reconstruction is a critical step as delivered dose for real-time adaptation will 
ultimately depend on the motion encountered. An isocentre shift method was utilised for 
volumes assumed to move with transponders (GTV and lung). The isocentre shift method 
considers each arc as many sub arcs each with isocentre shifted (in 2 mm bins) to mimic 
the motion. Treatment log files and the transponder trajectories were utilised to create a 
motion encoded treatment plan that was calculated in the planning system. Dose 
reconstruction was performed for spine and heart volumes assuming they were static. 
Reconstruction of the delivered conventional plan was performed for comparison. Delivery 
of the conventional plan assumed pre-treatment patient alignment and utilised treatment log 
files acquired in a dummy delivery and transponder motion from treatment sessions. The 
tracking plan was reconstructed on the end exhale phase CT while the conventional plan was 
reconstructed on the average CT. End-exhale GTV is used for both cases. For the 
reconstruction of the conventional plan, use of an average CT had <1% difference to  
calculation on the end exhale scan for this plan, which agrees with previous reports justifying 
dose calculation on average CT from 4DCT [30]. 
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Results 
 
We present data from the first patient treatment on 30th October 2015; an 80 y/o male with 
a single metastasis in the left lower lobe. He was positioned on his right side in a BodyFix 
bag due to the posterior distance to transponders from anterior chest wall preventing supine 
treatment (our normal setup) and patient performance preventing prone treatment. The 
internal peak to peak motion of the lesion at 4DCT was 10.8 mm, 4.8 mm, and 3.2 mm   in 
the superior–inferior (SI), left–right (LR) and anterior–posterior (AP) directions, 
respectively. The surrogate accuracy of the transponder centroid to the GTV centre 
determined in each phase of the 4DCT showed mean discrepancies of 1.2 mm, 0.6 mm and 
0.94 mm in the superior–inferior, lateral and anterior–posterior directions, respectively. 
Image artefacts in the 4DCT contributed to uncertainty in the determination of the surrogacy 
error; the beacon and GTV shape and size varied across the 10 breathing phases. The plan 
complexity for each plan was within acceptable range (<0.8) with MCS of 0.06 for the MLC 
tracking plan and 0.21–0.28 for the conventional ITV-based plan. The MLC tracking errors 
were minimal for delivery of the MLC tracking plan with mean AuAo of 2.26 cm
2 attributed 
to leaf adjustment (2.09cm2), leaf-fitting (0.43cm2 for arc 1 and 0.62cm2 for arc2) and 
target localisation error (0.62cm2 for arc 1 and 0.93cm2 for arc2). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 2. Comparison of Planning Target Volumes shows a significant reduction (41%) 
in the volume with MLC tracking delivery (A) compared to standard ITV-based 
planning (B). The red contour indicates the PTV on end exhale phase of 4DCT used 
for MLC tracking and the blue contour indicates the PTV on mean of 4DCT used for 
the ITV-based plan. Coronal view. 
  
The PTVTracking was 18.7 cc, 41% smaller than the PTV for standard planning (29.8 cc) (Fig. 
2). Targeting a smaller PTV translated to lower normal lung doses for this patient, with mean 
lung dose reduced by 31% or 0.6 Gy, V20 reduced by 35% or 48 cm3 and V5 reduced by 9% 
or 50 cm3. Dose maximum (D2%) reported to the spine was reduced from 5.1 to 3.8 Gy 
(33%). Plans had equivalent dose coverage for their respective PTV volumes. 
Treatments had an average appointment time of 90 min. A significant proportion of time was 
allocated to ensuring correct patient rotation due to the beacon centroid being offset from 
tumour and patient being positioned in the lateral decubitus position. Transponders were 
located 2.5, 2.1 and 2.5 cm from the lesion edge, all anterior and lateral. Through the four 
treatment fractions, the internal motion of the transponders ranged between 15.0–16.5 mm, 
3.4–3.7 mm, and 3.1–3.3 mm, in the SI, LR, and AP directions respectively, demonstrating 
substantially larger superior–inferior motion extent compared to simulation (Fig. 3). Fig. 3 
shows motion of the transponders during treatment to be larger than the ITV (motion 
observed during 4DCT) 22%, 32% and 31% of the time, in the SI, LR and AP directions 
respectively. Motion extending out-side the PTV, a 5 mm expansion of the ITV, occurred 
during treatment 2%, 1% and 2% of the time, in the CC, LR and AP directions respectively. 
Critically, this infers that a geometric miss would have occurred if ITV-based treatment 
would have been delivered with only pre-treatment imaging.  Furthermore, the components 
of the PTV margin expansion to account for inter-observer contouring variability, surrogacy 
accuracy and sub-clinical tumour growth, were utilised in full to account for tumour motion 
variation. Conventionally, SABR delivery does not deploy intra-treatment tumour 
monitoring so any geometric miss would have been undiscovered. The motion of the lesion 
and transponders with respiration captured in kV and MV images is shown in Fig. 4. A video 
of the kV and MV images acquired during treatment is provided as Supplementary material. 
Fig. 5 shows the delivered dose reconstructed onto the respective planning CT datasets 
over the four days of treatment for MLC tracking delivery and the conventional ITV-based 
plan. The planned dose to the GTV is equivalent between MLC tracking and no tracking. 
However the delivered doses for no tracking are lower than that planned: the mean GTV 
D95 across fractions is 106 ± 2% (range 103–108%) compared to 110% planned. This 
difference occurred due to the systematically larger motion experienced with this patient 
during treatment compared to simulation. The MLC tracking delivery provided mean GTV 
D95 doses of 110 ± 0.5% (range 109–110%) compared to 111% planned. Fig. 5 
demonstrates modest decreases in lung and heart doses and improved target coverage 
relative to the conventional plan. The MLC tracking delivery was also more reproducible 
(lower range of mean GTV D95 values) than the standard SABR delivery across fractions. 
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Discussion 
 
This paper reports on the first patient treatment with real-time adaptive treatment for lung 
cancer with MLC tracking. MLC tracking radiotherapy has previously been delivered to 
28 prostate patients with 858 successful treatment fractions.  MLC  tracking for lung SABR 
is more complicated than prostate MLC tracking: respiratory motion is larger, more 
frequent and faster than prostate motion, SABR delivering larger dose per fraction, and 
there is an increased importance of system latency mitigation with the use 
 
 
 
 
 
 
 
 
 
 
 Discussion 
This paper reports on the first patient treatment with real-time adaptive treatment for lung 
cancer with MLC tracking. MLC tracking radiotherapy has previously been delivered to 28 
prostate patients with 858 successful treatment fractions. MLC tracking for lung SABR is 
more complicated than prostate MLC tracking: respiratory motion is larger, more frequent 
and faster than prostate motion, SABR delivering larger dose per fraction, and there is an 
increased importance of system latency mitigation with the use of a prediction algorithm. 
The clinical issues are also different for lung SABR compared to prostate radiotherapy, 
with use of ITV based planning, baseline shifts of tumour position during respiration, 
irregular internal motion and in homogeneity. 
The patient in this study benefited from real-time adaptive treatment with a 41% smaller target 
volume, which is comparable to that reported for adaptive delivery with robotic and gimbal 
devices [11,12]. The extent of motion was significantly larger at treatment compared to that 
seen during 4DCT acquisition.  For the conventional ITV-based plan, motion exceeded the 
ITV ~30% of the time. For this case the PTV expansion of 5 mm has ensured coverage of 
the target is retained 98% of the time. However, the PTV expansion of 5 mm is derived 
to account for up to 5 mm inter-observer contouring variability, sub-clinical tumour 
extension and the measured 1-3 mm of surrogacy uncertainty with the beacon 
transponders. 
Internal peak to peak transponder motion for this patient was significantly larger than the 
motion amplitude determined from simulation 4DCT. We believe that this is due to the 
sampling that occurs with standard 4DCT reconstruction, which score peak exhale and inhale 
minimally based on the short time in these positions, compared to the transponder 
locations during treatment which are reported 20 times per second. 
The impact of MLC tracking will depend on the extent of tumour motion and patients with 
larger tumour motion will benefit from larger reductions in target volume and subsequent 
reductions in organ at risk doses. Even modest reduction of lung dose in absolute terms 
will benefit planning to isotoxic tolerances in the oligometastatic setting or for subsequent 
lesions. Furthermore, all patients potentially benefit if a baseline shift occurs from the 
gating enacted when the tumour moves outside the motion limits obtained from 
simulation. A similar level of dose coverage would have been achieved with a pure gating 
strategy; however, the efficiency of MLC tracking delivery is superior to gating strategies 
where a duty cycle of 30% is not uncommon. It should be noted however that 
introduction of flattening filter free delivery has reduced irradiation times, potentially 
improving the efficiency of gated treatments. 
MLC tracking is highly accessible as it requires only two key components; real-time 
target guidance and a multi-leaf collimator. The great majority of linear accelerators 
currently sold now have the MLC. This study utilised real time target guidance from 
electromagnetic transponders as they are a proven robust position signal, but localisation 
could equally be derived from other methods such as X-ray fluoroscopy, real-time 
magnetic resonance imaging, or external surrogates. The electromagnetic transponders 
provide an internal surrogate of the tumour and their location will affect the accuracy of 
their surrogate motion. Further research is directed towards markerless MLC tracking that 
would not require implantation of transponders, a potential source of toxicity, replaced 
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with direct (image-based) tracking [31–34]. 
Reporting delivered dose poses some challenges to classical application of the ICRU 
volumes for MLC tracking. In real-time adaptive radiotherapy, the PTVTracking can be 
considered time- resolved with its components defined in each respiratory phase to 
account for treatment uncertainty; in our implementation the PTV is equivalent across 
respiratory phases. This is contrasted to the PTV for conventional ITV-based planning, 
which should be defined in the classical way and is difficult to compare directly to 
PTVTracking. The more important metric is GTV coverage, which is maintained in this 
case. The PTV is a geometric tool to ensure GTV coverage, and for meaningful 
application with real-time adaptive treatment will require further data to development 
tolerances. 
 
Clinical translational relevance 
An emerging treatment delivery technology, MLC tracking has been translated in the clinic 
and used for real time adaptive radio- therapy with lung SABR for the first time. MLC 
tracking for real time adaptation with a standard linear accelerator improves target dose 
coverage, reduces organ at risk doses and is potentially highly accessible requiring only 
software change to be implemented on a modern linear accelerator. 
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